New drug cocktail could spare kidney transplant patients from lifelong steroids
NCT ID NCT02711202
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tested a new combination of two drugs, Alemtuzumab and Infliximab, given right after a kidney transplant to prevent rejection. The goal was to see if patients could avoid long-term steroids and calcineurin inhibitors. Twenty first-time kidney transplant recipients were enrolled and followed for one year to check survival, graft function, and rejection rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Alemtuzumab and Infliximab
- What this could lead to
- If successful, this approach could reduce the need for long-term steroids and calcineurin inhibitors after kidney transplant, potentially lowering side effects.
- What could go wrong
- This is a very small pilot study with only 20 patients, so results may not apply to everyone. The new regimen may not prevent rejection as well as standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI may spot hidden kidney transplant rejection
- A drug given to organ donors may help kidneys work faster after transplant
- Which diuretic protects a new kidney best? a Head-to-Head trial puts furosemide and mannitol to the test
- Blood test clues could make antifungal dosing safer for transplant patients
- New Two-Step therapy aims to stop chronic kidney transplant rejection
- Smartphone app and booklet could help kidney transplant patients stick to medications